Experimental drug shows promise for rare muscle diseases
NCT ID NCT04628936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the long-term safety and effectiveness of a drug called KZR-616 in 18 adults with active polymyositis or dermatomyositis, rare diseases that cause muscle inflammation and weakness. Participants who completed an earlier study received weekly injections of KZR-616 for up to 48 weeks. The main goal was to see if the drug improved muscle function and disease activity over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KZR-616 (zetomipzomib), a drug given as a weekly injection under the skin
What this could lead to
If successful, this could point toward a new treatment option for people with polymyositis or dermatomyositis, helping to control disease activity.
What could go wrong
This is a small, early-phase study with only 18 participants and no placebo comparison, so results may not apply broadly. The drug may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KZR Research Site
Beverly Hills, California, 90211, United States
-
KZR Research Site
Orange, California, 92868, United States
-
KZR Research Site
Miami, Florida, 33136, United States
-
KZR Research Site
Kansas City, Kansas, 66160, United States
-
KZR Research Site
Baltimore, Maryland, 21224, United States
-
KZR Research Site
Ann Arbor, Michigan, 48109, United States
-
KZR Research Site
Duncansville, Pennsylvania, 16635, United States
-
KZR Research Site
Pittsburgh, Pennsylvania, 15213, United States
-
KZR Research Site
Austin, Texas, 78756, United States
-
KZR Research Site
Prague, Czechia